The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity

Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412

(2010) C. M. Dayan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study

(2009) Greg Siller et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

The protein kinase C agonist PEP005 increases NF-κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

(2009) Astrid Marta Olsnes et al.   BRITISH JOURNAL OF HAEMATOLOGY

Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells

(2009) A. Ghoul et al.   CANCER RESEARCH

Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia

(2009) H. Reikvam et al.   CURRENT CANCER DRUG TARGETS

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation

(2009) Håkon Reikvam et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis

(2009) Lawrence Anderson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras

(2009) T Zhu et al.   ONCOGENE

Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies

(2009) Thuy T.T. Le et al.   VACCINE

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

(2008) K A Benhadji et al.   BRITISH JOURNAL OF CANCER

The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner

(2008) Peter Hampson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

(2008) Roberto Stasi   EXPERT OPINION ON BIOLOGICAL THERAPY

The PKC  -Abl complex communicates ER stress to the mitochondria - an essential step in subsequent apoptosis

(2008) X. Qi et al.   JOURNAL OF CELL SCIENCE

Protein kinase C signalling in leukemia

(2008) Amanda J. Redig et al.   LEUKEMIA & LYMPHOMA

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells

(2008) M. Serova et al.   MOLECULAR CANCER THERAPEUTICS